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Abstract
AIM: To compare ultrasound-based acoustic structure 
quantification (ASQ) with established non-invasive 
techniques for grading and staging fatty liver disease.
METHODS: Type 2 diabetic patients at risk of non-
alcoholic fatty liver disease (n  = 50) and healthy 
volunteers (n  = 20) were evaluated using laboratory 
analysis and anthropometric measurements, transient 
elastography (TE), controlled attenuation parameter 
(CAP), proton magnetic resonance spectroscopy 
(1H-MRS; only available for the diabetic cohort), 
and ASQ. ASQ parameters mode, average and focal 
disturbance (FD) ratio were compared with: (1) the 
extent of liver fibrosis estimated from TE and non-
alcoholic fatty liver disease (NAFLD) fibrosis scores; 
and (2) the amount of steatosis, which was classified 
according to CAP values.
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RESULTS: Forty-seven diabetic patients (age 67.0 ± 
8.6 years; body mass index 29.4 ± 4.5 kg/m²) with 
reliable CAP measurements and all controls (age 26.5 
± 3.2 years; body mass index 22.0 ± 2.7 kg/m²) were 
included in the analysis. All ASQ parameters showed 
differences between healthy controls and diabetic 
patients (P  < 0.001, respectively). The ASQ FD ratio 
(logarithmic) correlated with the CAP (r  = -0.81, P  
< 0.001) and 1H-MRS (r  = -0.43, P  = 0.004) results. 
The FD ratio [CAP < 250 dB/m: 107 (102-109), CAP 
between 250 and 300 dB/m: 106 (102-114); CAP 
between 300 and 350 dB/m: 105 (100-112), CAP ≥ 
350 dB/m: 102 (99-108)] as well as mode and average 
parameters, were reduced in cases with advanced 
steatosis (ANOVA P  < 0.05). However, none of the ASQ 
parameters showed a significant difference in patients 
with advanced fibrosis, as determined by TE and the 
NAFLD fibrosis score (P > 0.08, respectively).
CONCLUSION: ASQ parameters correlate with steatosis, 
but not with fibrosis in fatty liver disease. Steatosis 
estimation with ASQ should be further evaluated in 
biopsy-controlled studies.
Key words: Transient elastography; Non-alcoholic fatty 
liver disease; Liver stiffness; Non-alcoholic fatty liver 
disease; Fibrosis score; Controlled attenuation parameter
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Non-invasive characterization of hepatic 
steatosis and fibrosis is becoming important for the 
screening, diagnosis, and monitoring of patients with 
chronic liver diseases. This work compared acoustic 
structure quantification (ASQ) and established non-
invasive methods to characterize fatty liver disease. 
ASQ parameters differed between healthy controls and 
diabetic patients with fatty liver disease independent of 
the extent of fibrosis. The focal disturbance ratio and 
further ASQ parameters correlated with the severity of 
steatosis. Therefore, ASQ could be used to evaluate 
steatosis and merits further investigation; however, 
ASQ seems to be impractical to characterize fibrosis in 
patients with fatty liver disease. 
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INTRODUCTION
Non-invasive characterization of hepatic steatosis and 
fibrosis are attracting growing scientific and medical 
interest for the screening, diagnosis, and monitoring 
of patients with chronic liver diseases[1-3]. In particular, 
fibrosis staging by means of elastography is highly 
accurate for detecting advanced liver injury and has, 
therefore, been progressively implemented in clinical 
practice[1]. 
In addition to fibrosis characterization, non-invasive 
quantification of hepatic fat content has attracted 
increasing attention in terms of both risk assessment 
and monitoring of patients with non-alcoholic fatty 
liver disease (NAFLD) and liver diseases from other 
etiologies[1,4]. The controlled attenuation parameter 
(CAP) - computed by commercial software that comes 
with the transient elastography device (Fibroscan) 
- correlates steatosis with the signal attenuation 
during liver stiffness measurement (LSM), and is very 
accurate to detect advanced hepatic steatosis[5-9]. 
Moreover, magnetic resonance based techniques (e.g., 
proton magnetic resonance spectroscopy, 1H-MRS) 
allow quantification of the hepatic lipid fraction, an 
additional parameter of the severity of steatosis[10,11]. 
However, these approaches are affected by high costs 
and limited availability (1H-MRS) or by anthropometry 
(CAP)[4,8]. 
Analysis of B-Mode ultrasound may represent a 
further option for the non-invasive grading and staging 
of liver damage, as conventional sonography is highly 
sensitive to subtle changes in tissue texture[12,13]. 
However, comparison of gray scale images is operator-
dependent and also varies with some technical 
parameters[12]. Computerized analysis of acoustic tissue 
properties may overcome these limitations: acoustic 
structure quantification (ASQ) software analyzes 
the characteristic intensity pattern (“speckles”) of 
conventional B-Mode ultrasound and compares its 
distribution histogram with a theoretical probability 
density function (PDF, Rayleigh distribution) of the 
echo amplitude[13,14]. Histology-based studies have 
reported that ASQ parameters correlate with the degree 
of fibrosis in patients with liver diseases of different 
etiologies[13-15]. Moreover, a pilot study revealed strong 
agreement between ASQ values and hepatic fat 
accumulation in an animal model[16]. 
ASQ results have not yet been compared with those 
of established non-invasive techniques. Therefore, 
we prospectively compared ASQ measurements in 
healthy controls and diabetic patients at risk for NAFLD 
or associated liver injury with TE and CAP values 
(reference standards) as well as 1H-MRS results and 
serum based NAFLD fibrosis scores.
MATERIALS AND METHODS
Patients and controls
The study was reviewed and approved by the local 
ethics committee (University of Leipzig, register no. 
358/08-B-ff and No. 419-12-17122012) and performed 
in accordance with the ethical guidelines of the Helsinki 
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Declaration. Written informed consent was obtained 
from all participants before study enrollment.
Between April 2013 and March 2014, outpatients 
with type 2 diabetes mellitus at risk of NAFLD and 
without other liver diseases were recruited. For the 
control group, healthy volunteers with no history of any 
chronic liver disease, diabetes mellitus, or metabolic 
syndrome, were recruited. Increased ultrasound 
echogenicity of the liver parenchyma (compared 
with the right renal cortex) or CAP > 252 dB/m were 
regarded as exclusion criteria for the control group[5]. 
Significant alcohol intake (weekly consumption > 210 g 
for men and 140 g for woman, respectively) was ruled 
out for the total study cohort before inclusion[17]. 
For all participants, anthropometric examination, 
ultrasound, LSM (transient elastography, M probe), 
CAP assessment and laboratory parameters (patients 
only) were performed on the same day after a fasting 
period of at least three hours. 1H-MRS was performed 
either on the same day or after 6 mo during follow-up 
visits.
Laboratory assessment and NAFLD fibrosis score
Albumin, blood count, and serum levels of amino-
transferases (ALT and AST) were determined for all 
diabetic patients. Individuals with highly elevated 
aminotransferases (at least five times the upper normal 
limit) were excluded from further examinations because 
of the risk of inaccurate LSM.
The NAFLD fibrosis score was calculated according 
to Angulo et al[18]: Score = -1.675 + 0.037 × age 
(years) + 0.094 × body mass index (kg/m2) + 1.13 × 
diabetes (yes 1, no 0) + 0.99 × AST/ALT ratio - 0.013 
× platelet (Gpt/l) - 0.66 × albumin (g/dL). A score 
of at least 0.676 indicated high risk of advanced liver 
fibrosis[18].
Ultrasound, elastography, and controlled attenuation 
parameter
All subjects underwent conventional ultrasound to 
rule out mechanical cholestasis. LSM was performed 
using the M probe of transient elastography (TE; 
Fibroscan, Echosens, Paris, France). According to the 
manufacturer’s recommendation, examinations with 
fewer than 10 valid measurements or an interquartile 
range > 30% of the median LSM value (only in cases 
with liver stiffness ≥ 7.1 kPa) were excluded from 
further analysis[19]. TE values ≥ 7.9 kPa indicated the 
presence of advanced fibrosis[20].
The CAP gives additional information about the 
attenuation of ultrasonic signals during TE examination. 
CAP computation is included in the TE software, and 
the results (CAP, LSM) are shown together[21]. CAP was 
only considered when TE measurements were valid 
and reliable[5,21]. CAP served as reference method; 
therefore, only cases with valid CAP results were 
included in the final analysis. CAP values ≥ 252 dB/m 
indicated fatty liver disease[5], and values ≥ 300 dB/m 
were regarded as advanced steatosis[8]. No patient 
had values between 250 and 252 dB/m; therefore, the 
diabetic subjects were classified into four groups to 
better present the data: (1) CAP < 250 dB/m; (2) CAP 
≥ 250 and < 300 dB/m; (3) CAP ≥ 300 and < 350 
dB/m; and (4) CAP ≥ 350 dB/m.
Acoustic structure quantification
Analytical method: The ASQ software analyzes 
the linear raw data from ultrasound B-mode images. 
It provides a number of tissue parameters that are 
related to the scattering of echoes in user-defined 
region of interests (ROI). The histogram of the 
measured intensity distribution in the B-mode image 
ROI is essentially compared with the PDF of an ideal, 
homogenous scatterer (Rayleigh distribution)[22]. ASQ 
subdivides the primary ROI into a large number of (up 
to 1000) secondary ROIs and displays the so-called C2-
histogram of the distribution of frequency ratios given 
by frequency of the ratio 
C2 = σ2/σR2, where σ and σR stand for the standard 
deviations of measured and estimated (Rayleigh) PDFs, 
respectively[13]. In the liver, ASQ uses an empirical cut-off 
parameter α and reports slightly modified parameters σ 
m and Cm2 instead to minimize the influence of individual 
strong scatterers[13].
Mode (value with highest appearance, “peak 
value”), average and SD are then derived from the C2 
or Cm2 histogram. A more recent ASQ implementation 
computes two curves (displayed in red and blue), 
depending on whether the variation in α quantitatively 
changes the σ parameter by less (depicted in red) or 
more (depicted in blue) than an empirical percentage 
(20%), respectively. The focal disturbance (FD) ratio is 
then defined as the ratio of the areas under the curve 
between the red and blue curve[16].
ASQ imaging: In the present study, B-mode images 
of the right liver lobe were recorded in the region 
of LSM and CAP acquisition using a curved array 
transducer (PVT-375 BT 3.5 MHz) and an Aplio 
500 ultrasound scanner (Toshiba Medical Systems, 
Otawara, Japan). Display depth and focus were fixed 
at 10 and 5.5 cm, respectively. The ultrasound signal 
gain was set to 90%. A raw data loop of 2-3 s was 
recorded using the ASQ preset mode and files were 
exported to a PC workstation in DICOM format. ASQ 
was analyzed with the vendor’s software (PC-ASQR, 
Aplio500, Version 1.01R000). Mode, average and FD 
ratio were computed in four ROIs covering most of the 
liver parenchyma, but avoiding larger vessels and bile 
ducts (Figure 1). The respective mean ASQ values of 
five separate frames were computed to obtain more 
reliable measures for each subject.
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fat peaks were corrected for T2 relaxation (using MR 
spectra at different echo times) and were used to 
calculate the hepatic fat fraction[8]. 
Data processing and statistical methods
All parameters were recorded in a spreadsheet file 
(Microsoft Excel, Microsoft). Statistical testing was 
carried out using commercial software (MedCalc 14.12, 
MedCalc Software, Ostend, Belgium). Data were 
expressed either as mean ± SD or median and range, 
as appropriate. 
Fisher’s exact test and χ 2 tests were used to test 
for the association of variables. Nonparametric tests 
(Mann-Whitney U test, Kruskal-Wallis test) were used 
to compare median values of independent samples, 
where post-hoc pair-wise comparisons were performed 
according to Conover[23]. For mean values, the t-test 
was applied. The Pearson correlation coefficient 
was calculated to analyze the degree of association 
between two variables. P values < 0.05 indicated a 
significant difference. Diagnostic performance of ASQ 
parameters was analyzed using receiver operating 
characteristic (ROC) curves. 
The statistical methods of this study were reviewed 
by PD Dr. David Petroff (IFB Adiposity Diseases, 
Leipzig University Medical Center/Clinical Trial Center, 
University of Leipzig, Leipzig, Germany).
RESULTS
Clinical characteristics of the study cohort
Fifty patients with type 2 diabetes mellitus and 
20 healthy volunteers were recruited. TE and CAP 
were available in 47 of the diabetic patients (94%): 
three subjects had an invalid measurement (two 
males, all cases with fewer than ten valid shots) 
and where excluded from further analysis. 1H-MRS 
was available for n = 43 diabetic patients because 
of contraindications and technical reasons in four 
cases. The characteristics of the analyzed cohort are 
displayed in Table 1.
Magnetic resonance spectroscopy
The majority of patients (79%) underwent 1H-MRS 
on the same or the following day of ASQ and TE 
examinations. In 21% of the cases, the time interval 
between ultrasound examination and 1H-MRS was 6.5 
mo (range: 6.2-7.3 mo) for technical reasons.
1H-MRS was performed as described previously 
with some technical modifications[8]. In brief, T2-
corrected, single-voxel MR spectra were acquired on 
a 1.5-T scanner (Achieva XR, Philips Healthcare, Best, 
Netherlands) using local shimming and a stimulated-
echo acquisition method (STEAM). Voxels sized 20 mm 
× 20 mm × 20 mm were placed in liver segment Ⅶ, 
avoiding larger bile ducts and vessels. Spectroscopic 
data were acquired without water suppression, using 
the following sequence parameters: repetition time, TR 
= 3.000 ms; number of echoes, 5; echo times 10-50 
ms; 2048 data points; bandwidth 1.000 Hz/pixel; 40 
averages; total acquisition time 270 s. MR spectra 
were analyzed using a commercial tool (LCModel 6.3, 
Oakville, Canada) that determines the relative hepatic 
lipid concentrations. Calculated areas of water and 
Figure 1  Acoustic structure quantification analysis of liver tissue. Four separate regions of interest were drawn to cover most of the parenchyma, but avoiding 
large vessels. The acoustic structure quantification software automatically calculated the parameters mode, average and standard deviation for both curves of the 
histogram (green frame), as well as the ratio of the areas under both curves (focal disturbance ratio, red frame). 
Table 1  Clinical characteristics of the study cohort  n  (%)
Parameter Healthy controls Type 2 diabetes 
mellitus
Sex (F/M) 10/10 23/24
Age (yr) 26.5 ± 3.2 67.0 ± 8.6b
Body mass index (kg/m²) 22.0 ± 2.7 29.4 ± 4.5b
   < 25 kg/m² 19 (95)   7 (15)
   25-30 kg/m² 1 (5) 21 (45)
   > 30 kg/m² - 19 (40)
Waist-to-hip ratio 0.85 ± 0.08 0.97 ± 0.08b
   < 1.0 19 (95) 27 (57%)
   ≥ 1.0 1 (5) 20 (43%)
CAP (dB/m)        192 (151-237)      329 (100-396)d
   < 250 dB/m  20 (100)   6 (13)
   250-300 dB/m - 10 (21)
   300-350 dB/m - 19 (40)
   > 350 dB/m - 12 (26)
bP < 0.01 vs controls; dP < 0.01 vs controls by design. Controls were 
excluded if CAP > 252 dB/m. CAP: Controlled attenuation parameter.
Karlas T et al . ASQ for characterization of liver disease
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Non-invasive fibrosis estimation with ASQ vs TE and 
NAFLD score
LSM values (logarithmic) showed good correlation 
with NAFLD fibrosis scores: r = 0.46 (0.20; 0.66), P = 
0.0012. None of the healthy controls had elevated TE, 
whereas advanced hepatic fibrosis was considerable in 
the diabetic cohort: ten patients (21%) had LSM > 7.9 
kPa and 12 patients (26%) had NAFLD scores > 0.676.
The association of ASQ parameters mode, average, 
and FD ratio was analyzed according to the risk of 
hepatic fibrosis. All parameters showed differences 
between healthy controls and diabetic patients (Figures 
1 and 2). No significant association of mode and 
average for both (blue and red) C2-histogram curves 
was observed in diabetic patients, independent of 
the presence of fibrosis as defined by TE (Figure 2) 
or NAFLD score (P-values >0.08, respectively). In 
addition, FD ratios did not differ between both groups 
of diabetic patients: 0.060 (0.044; 0.076) vs 0.053 
(0.037; 0.089) (TE cut-off, P = 0.640) and 0.059 
(0.030; 0.125) vs 0.057 (0.047; 0.071) (NAFLD 
fibrosis score cut-off, P = 0.946), respectively.
Non-invasive steatosis characterization with ASQ vs 
CAP and 1H-MRS
Diabetic patients were classified according to the 
degree of fatty liver disease, defined by CAP values: 
only n = 6 cases were at low risk for fatty liver 
(CAP < 250 dB m), whereas n = 33 were above the 
highly specific cut-off level (CAP > 300 dB/m) for 
advanced hepatic steatosis[8]. Gender distribution 
did not differ between healthy controls and the four 
diabetes subgroups, whereas BMI was increased in 
patients with advanced hepatic steatosis (Table 2). 
Furthermore, 1H-MRS revealed a positive correlation 
between CAP and the hepatic fat fraction [n = 43; r = 
0.5 (0.31; 0.73), P < 0.001] (cf. also Table 2).
ASQ parameters mode and average of both C2-
histogram curves and FD ratio differed between 
healthy controls and diabetic patients (P-values 
< 0.001). They also showed a stepwise decrease 
according to the CAP-defined classification of steatosis 
in diabetic patients (Table 2, Figure 3). ROC analysis 
for the detection of advanced steatosis (defined by 
CAP > 300 dB/m) in diabetic patients by the FD ratio 
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revealed an area under the curve (accuracy) of 0.76 
(0.61; 0.87) (sensitivity 97%, specificity 50%) at a 
cut-off value of 0.092. With the addition of control 
subjects, the accuracy increased to 0.89 (sensitivity 
97%, specificity 78%) with the same cut-off.
As with the CAP results (Figure 3B), ASQ parameters 
were negatively correlated with 1H-MRS in the diabetic 
cohort (Table 2), e.g., r = -0.43 (-0.65; -0.15), P 
= 0.004 for the FD ratio. Agreement between both 
methods increased when only cases with a hepatic fat 
fraction < 25% were considered (n = 36): r = -0.64 
(-0.80; -0.40), P < 0.001.
DISCUSSION
The present study provided a comprehensive 
comparison of the ASQ technique with established 
non-invasive methods for the grading and staging 
of fatty liver disease. Our data underline the value 
of ASQ for the quantification of liver fat: the FD ratio 
showed a strong correlation with the CAP method, 
which in turn achieved high diagnostic accuracy 
for the grading of liver steatosis compared with 
liver histology[1,4-9]. Furthermore, the FD ratio also 
correlated with the hepatic lipid fraction, as quantified 
by 1H-MRS, especially in cases with low to moderate 
hepatic fat content. These results confirm data from 
a mouse model, which demonstrated the potential 
value of the refined ASQ algorithm for non-invasive 
liver fat quantification[16]. Our findings are also in 
line with preliminary observations on the regression 
of FD ratios in NAFLD patients treated for morbid 
obesity[24]. Therefore, ASQ may become a novel tool 
for the estimation of hepatic steatosis that is equally as 
Table 2  Distribution of anthropometry, hepatic lipid content, fibrosis risk and acoustic structure quantification parameters in 
different grades of fatty liver  n  (%)
Parameter Controls Type 2 diabetes mellitus
CAP < 250 dB/m CAP 250-< 300 dB/m CAP 300-< 350 dB/m CAP ≥ 350 dB/m
Sex (F/M) 10/10 2/4 6/4 8/11 7/5
Body mass index (kg/m²)b 22.0 ± 2.7 26.7 ± 4.6 28.3 ± 5.1 29.2 ± 4.3 32.1 ± 3
Waist-to-hip ratiob   0.85 ± 0.08   1.00 ± 0.03   0.91 ± 0.13   0.98 ± 0.06      1.01 ± 0.05
Liver stiffness (kpa)a 4.9 (2.9-6.8) 3.5 (3-6.1) 5.1 (3.5-11.7) 5.7 (3.4-12.3) 6.9 (4.1-70.6)
≥ 7.9 kpac 0 (0) 0 (0) 1 (10) 5 (26) 4 (33)
NAFLD fibrosis score - -0.68 (-2.45-1.25) 0.29 (-0.3-1.26) -0.4 (-3.04-1.1)  0.11 (-1.68-2.28)
≥ 0.676 1 (17) 3 (30) 2 (11) 4 (33)
1H-MR spectroscopy -   4.19 (2.69-16.62)    9.77 (1.56-15.71) 18.99 (5.66-35.55) 18.38 (9.42-41.11)
(relative lipid signal, %)
Asq
   Mode 1 (red histogram)b 114 (105-121) 107 (102-109) 106 (102-114) 105 (100-112) 102 (99-108)
   Average 1 (red histogram)a 117 (109-125) 110 (104-116) 108 (106-114) 106 (103-112)   105 (102-112)
   Mode 2 (blue histogram)b 126 (110-135) 117 (114-126) 119 (105-125) 114 (107-119)   114 (105-121)
   Average 2 (blue histogram)b 132 (116-149) 122 (116-139) 123 (114-130) 118 (109-134)   115 (106-123)
   Focal disturbance (FD) ratiob  0.34 (0.12-0.71)  0.16 (0.03-0.36)  0.07 (0.03-0.18)  0.06 (0.02-0.09)    0.04 (0.02-0.13)
aP < 0.05 (Kruskal-Wallis test), bP < 0.01 (Kruskal-Wallis test) vs healthy controls; cP < 0.05 (exact test for count data), vs healthy controls. ASQ: Acoustic 
structure quantification; CAP: Controlled attenuation parameter.
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accurate as other non-invasive methods[4].
ASQ was originally developed as an alternative 
to liver biopsy for fibrosis staging. Three biopsy-
controlled, cross-sectional studies have shown a 
correlation of ASQ parameters (mode and average) 
with the extent of liver fibrosis[13-15]. However, these 
ASQ parameters correlated with CAP results and thus 
with the degree of liver steatosis in our cohort (Table 
2). All ASQ parameters also differed between healthy 
controls and patients at risk of fatty liver disease, 
independent of the extent of fibrosis. By contrast, 
none of these parameters were associated with either 
the NAFLD fibrosis score or liver tissue stiffness, 
although both approaches represent well-established 
surrogates of liver fibrosis[3,4]. We therefore assumed 
that anthropometric factors and advanced steatosis, 
which were associated with a higher frequency of 
increased liver stiffness in our cohort, interfered with 
fibrosis in the B-mode speckle pattern and thus limited 
the prognostic value of ASQ for fibrosis in such cases. 
The three previous studies where ASQ correlated with 
fibrosis were performed either in lean cohorts without 
advanced steatosis and cirrhosis[13], in patients with 
homogeneous steatosis for all fibrosis stages[14], or 
did not analyze the impact of steatosis on ASQ results 
in detail[15]. Furthermore, the study of Ricci et al[15] 
reported low diagnostic accuracy of ASQ for fibrosis 
detection (AUROC 0.71 for any grade) in patients with 
viral hepatitis, which may be associated with steatosis 
especially for cases with progressive fibrosis[25]. Thus, 
our results may demonstrate a limited value of ASQ for 
characterizing fibrosis in the presence of steatosis. This 
finding is supported by recent data from a histology-
controlled cohort where ASQ proved imprecise in 
assessing liver fibrosis[26].
Our study had some limitations: quantitative 
analysis of ASQ parameters is still an experimental 
approach and the method has not yet been 
standardized (e.g., position and size of B-Mode ROIs, 
number of measurements, technical ultrasound 
parameters). Most previous ASQ studies did not 
adequately describe their data acquisition[13,15], which 
prevented a proper comparison with our results. 
Another source of discrepancy in fibrosis detection 
is a vendor’s update to the ASQ data processing[16] 
that came with the introduction of the FD ratio[13-15]. 
Furthermore, we only correlated ASQ results with 
other non-invasive detection techniques because liver 
histology was ethically prohibited in this pilot study 
and only provides a semi-quantitative estimate of 
steatosis[8]. However, an impact of the non-invasive 
reference methods on our study findings cannot 
be ruled out. As has been discussed previously[8], 
anthropometric factors, as well as the extent of liver 
fat, can alter liver stiffness, CAP and MR spectroscopic 
results[27-31]. In particular, MR techniques are 
susceptible to fibrosis-related iron deposits and may 
not properly discriminate between advanced grades of 
hepatic steatosis[27,28]. This could explain the moderate 
correlation between 1H-MRS and ASQ in our cohort, 
where advanced steatosis and fibrosis was highly 
prevalent. Accordingly, the findings of our pilot study 
should be further verified in histology-controlled 
studies.
In conclusion, our results provided the first evidence 
that ASQ FD ratio could be used for non-invasive 
evaluation of hepatic steatosis in patients at risk of 
fatty liver disease, and merits further investigation. In 
its current implementation, the ASQ algorithm seems 
to be impractical to characterize fibrosis in patients 
with fatty liver disease. There is also a need for biopsy-
controlled studies to further validate ASQ parameters 
and to evaluate critical factors, such as data acquisition 
or patient anthropometry. 
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